{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:53:52Z","timestamp":1775832832367,"version":"3.50.1"},"reference-count":215,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82350710226"],"award-info":[{"award-number":["82350710226"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370134"],"award-info":[{"award-number":["82370134"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970112"],"award-info":[{"award-number":["81970112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370178"],"award-info":[{"award-number":["82370178"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23ZR1439900"],"award-info":[{"award-number":["23ZR1439900"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23S11900400"],"award-info":[{"award-number":["23S11900400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFA1800401"],"award-info":[{"award-number":["2023YFA1800401"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.blre.2024.101220","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T19:38:09Z","timestamp":1717789089000},"page":"101220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk"],"prefix":"10.1016","volume":"67","author":[{"given":"Jiayi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kankan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J Epidemiol Glob Health"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6024","key":"10.1016\/j.blre.2024.101220_bb0020","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0025","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1172\/JCI83871","article-title":"Cancer immunotherapy: harnessing the immune system to battle cancer","volume":"125","author":"Yang","year":"2015","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"6165","key":"10.1016\/j.blre.2024.101220_bb0040","first-page":"1432","article-title":"Breakthrough of the year 2013","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Cancer Immunotherapy Sci"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0045","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.blre.2024.101220_bb0050","doi-asserted-by":"crossref","first-page":"8305","DOI":"10.3390\/ijms21218305","article-title":"Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies?","volume":"21","author":"Hosseinkhani","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0055","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.blre.2024.101220_bb0060","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2024.101220_bb0065","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"7528","key":"10.1016\/j.blre.2024.101220_bb0070","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.blre.2024.101220_bb0075","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb0080","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.blre.2024.101220_bb0090","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0095","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0100","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","article-title":"PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations","volume":"15","author":"Jiang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0115","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7555\/JBR.31.20160168","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"32","author":"Webb","year":"2018","journal-title":"J Biomed Res"},{"issue":"21","key":"10.1016\/j.blre.2024.101220_bb0125","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"6230","key":"10.1016\/j.blre.2024.101220_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0140","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0155","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis - from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cvr\/cvs217","article-title":"Endothelial shear stress in the evolution of coronary atherosclerotic plaque and vascular remodelling: current understanding and remaining questions","volume":"96","author":"Wentzel","year":"2012","journal-title":"Cardiovasc Res"},{"issue":"17","key":"10.1016\/j.blre.2024.101220_bb0170","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week","volume":"72","author":"Libby","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7855","key":"10.1016\/j.blre.2024.101220_bb0175","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002916","article-title":"Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem","volume":"9","author":"Poels","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11912-019-0796-0","article-title":"Cardiovascular disease and cancer: is there increasing overlap?","volume":"21","author":"Vincent","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0190","doi-asserted-by":"crossref","first-page":"994","DOI":"10.5551\/jat.RV17027","article-title":"Mechanism and management of cancer chemotherapy-induced atherosclerosis","volume":"25","author":"Mukai","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0195","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/HCO.0000000000000404","article-title":"Radiotherapy, chemotherapy and atherosclerosis","volume":"32","author":"Min","year":"2017","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.blre.2024.101220_bb0200","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2019.06.021","article-title":"Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute retrospective study","volume":"120","author":"Bar","year":"2019","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0205","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.amjcard.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am J Cardiol"},{"issue":"48","key":"10.1016\/j.blre.2024.101220_bb0210","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cancers12010067","article-title":"Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? mechanisms and impact in non-small cell lung cancer patients","volume":"12","author":"Nichetti","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.blre.2024.101220_bb0220","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2024.101220_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102280","article-title":"Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: a systematic review and meta-analysis","volume":"100","author":"Giustozzi","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.blre.2024.101220_bb0230","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.thromres.2020.09.038","article-title":"Venous and arterial thromboembolic events with immune checkpoint inhibitors: a systematic review","volume":"196","author":"Solinas","year":"2020","journal-title":"Thromb Res"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2024.101220_bb0235","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"issue":"11","key":"10.1016\/j.blre.2024.101220_bb0240","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/eurheartj\/ehaa779","article-title":"Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an american population-based cohort study","volume":"42","author":"Wang","year":"2021","journal-title":"Eur Heart J"},{"issue":"10203","key":"10.1016\/j.blre.2024.101220_bb0250","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(19)31674-5","article-title":"Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases","volume":"394","author":"Strongman","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0255","article-title":"Immunotherapeutic strategies in cancer and atherosclerosis-two sides of the same coin","volume":"13","author":"Nettersheim","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0260","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J Clin Invest"},{"issue":"43","key":"10.1016\/j.blre.2024.101220_bb0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol"},{"issue":"48","key":"10.1016\/j.blre.2024.101220_bb0270","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1093\/eurheartj\/ehz460","article-title":"Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study","volume":"40","author":"Abdel-Qadir","year":"2019","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.blre.2024.101220_bb0275","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2024.101220_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.652186","article-title":"Immune checkpoint inhibitors and atherosclerotic vascular events in cancer patients","volume":"8","author":"Inno","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0285","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/cancers14030730","article-title":"Platelet and cancer-cell interactions modulate cancer-associated thrombosis risk in different cancer types","volume":"14","author":"Palacios-Acedo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0290","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41569-018-0110-0","article-title":"Platelet biology and functions: new concepts and clinical perspectives","volume":"16","author":"van der Meijden","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"39","key":"10.1016\/j.blre.2024.101220_bb0295","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0300","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1161\/CIRCRESAHA.115.307016","article-title":"Platelet-mediated thrombosis: from bench to bedside","volume":"118","author":"Gurbel","year":"2016","journal-title":"Circ Res"},{"issue":"13","key":"10.1016\/j.blre.2024.101220_bb0305","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101220_bb0310","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3389\/fimmu.2019.01805","article-title":"Platelets, thrombo-inflammation, and cancer: collaborating with the enemy","volume":"10","author":"Palacios-Acedo","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2024.101220_bb0315","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2016.01.006","article-title":"Role of platelets in cancer and cancer-associated thrombosis: experimental and clinical evidences","volume":"139","author":"Mezouar","year":"2016","journal-title":"Thromb Res"},{"issue":"22","key":"10.1016\/j.blre.2024.101220_bb0320","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.2019001388","article-title":"Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin","volume":"134","author":"Suzuki-Inoue","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0325","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJMra0801082","article-title":"Mechanisms of thrombus formation","volume":"359","author":"Furie","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.bjp.0705606","article-title":"Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins","volume":"141","author":"Alonso-Escolano","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0335","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3390\/cancers13092260","article-title":"Alterations of the platelet proteome in lung cancer: accelerated F13A1 and ER processing as new actors in hypercoagulability","volume":"13","author":"Ercan","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0340","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/biomedicines9030228","article-title":"Oral squamous cell carcinoma is associated with a low thrombosis risk due to storage Pool deficiency in platelets","volume":"9","author":"Haen","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.blre.2024.101220_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.704945","article-title":"P2RY12-inhibitors reduce cancer-associated thrombosis and tumor growth in pancreatic cancers","volume":"11","author":"Palacios-Acedo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.blre.2024.101220_bb0350","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.atherosclerosis.2020.04.018","article-title":"Platelet-leukocyte interplay during vascular disease","volume":"307","author":"Schrottmaier","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.blre.2024.101220_bb0355","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fcvm.2017.00067","article-title":"Cancer and thrombotic risk: the platelet paradigm","volume":"4","author":"Lee","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0360","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCRESAHA.117.310795","article-title":"Circulating platelets as mediators of immunity, inflammation, and thrombosis","volume":"122","author":"Koupenova","year":"2018","journal-title":"Circ Res"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0365","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0370","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/ijc.28997","article-title":"Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo","volume":"136","author":"Mezouar","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.blre.2024.101220_bb0375","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cca.2020.02.019","article-title":"PD-1\/PD-L1 in cardiovascular disease","volume":"505","author":"Sun","year":"2020","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb0380","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11912-020-00925-8","article-title":"New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity","volume":"22","author":"Khunger","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0385","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.3390\/cells9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0390","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.amjms.2018.11.017","article-title":"Hepatotoxicity and recurrent NSTEMI while on pembrolizumab for metastatic Giant cell bone tumor","volume":"357","author":"Kwan","year":"2019","journal-title":"Am J Med Sci"},{"issue":"11","key":"10.1016\/j.blre.2024.101220_bb0395","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1161\/CIRCRESAHA.120.316770","article-title":"Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics","volume":"127","author":"Depuydt","year":"2020","journal-title":"Circ Res"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0400","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1161\/CIRCRESAHA.117.312513","article-title":"Atlas of the immune cell repertoire in mouse atherosclerosis defined by single-cell RNA-sequencing and mass cytometry","volume":"122","author":"Winkels","year":"2018","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0405","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb0410","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0415","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010037","article-title":"CD8(+) T cells in atherosclerosis","volume":"10","author":"Schafer","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.blre.2024.101220_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.740531","article-title":"Stimulation of the PD-1 pathway decreases atherosclerotic lesion development in Ldlr deficient mice","volume":"8","author":"Grievink","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0425","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41467-021-26282-z","article-title":"Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy","volume":"12","author":"Abbas","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0430","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0435","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0440","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jaccao.2020.08.007","article-title":"Immune checkpoint inhibitor therapy aggravates T cell-driven plaque inflammation in atherosclerosis","volume":"2","author":"Poels","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.blre.2024.101220_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0450","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/annonc\/mdx718","article-title":"Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?","volume":"29","author":"Gelsomino","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2024.101220_bb0455","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920913801","article-title":"New disappearance of complicated atheromatous plaques on rechallenge with PD-1\/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event","volume":"12","author":"Lamberti","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.blre.2024.101220_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100694","article-title":"Platelet activation and prothrombotic mediators at the nexus of inflammation and atherosclerosis: potential role of antiplatelet agents","volume":"45","author":"Lordan","year":"2021","journal-title":"Blood Rev"},{"issue":"24","key":"10.1016\/j.blre.2024.101220_bb0465","doi-asserted-by":"crossref","first-page":"9760","DOI":"10.3390\/ijms21249760","article-title":"Targeting platelet in atherosclerosis plaque formation: current knowledge and future perspectives","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2024.101220_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.886132","article-title":"Platelet-derived exosomes and atherothrombosis","volume":"9","author":"Wei","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.blre.2024.101220_bb0475","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet activation and atherothrombosis","volume":"357","author":"Davi","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0480","first-page":"162","article-title":"New concepts and mechanisms of platelet activation signaling","volume":"32","author":"Estevez","year":"2017","journal-title":"Physiology (Bethesda)"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0485","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-017-9677-x","article-title":"Normal platelet function","volume":"36","author":"Holinstat","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0490","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1007\/s00125-021-05498-0","article-title":"Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus","volume":"64","author":"Kohlmorgen","year":"2021","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0495","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1055\/s-0039-1692983","article-title":"Platelet-neutrophil crosstalk in atherothrombosis","volume":"119","author":"Pircher","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101220_bb0500","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.atherosclerosis.2020.07.008","article-title":"Platelets and coagulation factors: established and novel roles in atherosclerosis and atherothrombosis","volume":"307","author":"Koenen","year":"2020","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0505","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/pr.117.014530","article-title":"Platelet signaling and disease: targeted therapy for thrombosis and other related diseases","volume":"70","author":"Yeung","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"15","key":"10.1016\/j.blre.2024.101220_bb0510","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2021012441","article-title":"An alternate covalent form of platelet alphaIIbbeta3 integrin that resides in focal adhesions and has altered function","volume":"138","author":"Pijning","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0515","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ceb.2012.08.011","article-title":"Inside-out, outside-in, and inside-outside-in: G protein signaling in integrin-mediated cell adhesion, spreading, and retraction","volume":"24","author":"Shen","year":"2012","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-019-0709-6","article-title":"Platelet integrin \u03b1IIb\u03b23: signal transduction, regulation, and its therapeutic targeting","volume":"12","author":"Huang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0525","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-019-0709-6","article-title":"Platelet integrin alphaIIbbeta3: signal transduction, regulation, and its therapeutic targeting","volume":"12","author":"Huang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0530","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1161\/ATVBAHA.114.303413","article-title":"Current state and novel approaches of antiplatelet therapy","volume":"35","author":"Metharom","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"20","key":"10.1016\/j.blre.2024.101220_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012546","article-title":"Platelet-derived exosomes in atherosclerosis","volume":"23","author":"Gardin","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0540","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/cells11061014","article-title":"Platelets, a key cell in inflammation and atherosclerosis progression","volume":"11","author":"Huilcaman","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb0545","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1084\/jem.20012044","article-title":"A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation","volume":"196","author":"Massberg","year":"2002","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0550","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1160\/TH07-03-0207","article-title":"PSGL-1 regulates platelet P-selectin-mediated endothelial activation and shedding of P-selectin from activated platelets","volume":"98","author":"Dole","year":"2007","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0555","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1172\/JCI26885","article-title":"Platelet genomics and proteomics in human health and disease","volume":"115","author":"Macaulay","year":"2005","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0560","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.thromres.2010.10.010","article-title":"Platelets as immune mediators: their role in host defense responses and sepsis","volume":"127","author":"Li","year":"2011","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0565","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s12079-022-00676-0","article-title":"Platelet-lymphocyte co-culture serves as an ex vivo platform of dynamic heterotypic cross-talk","volume":"16","author":"Albayati","year":"2022","journal-title":"J Cell Commun Signal"},{"issue":"6667","key":"10.1016\/j.blre.2024.101220_bb0570","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/35393","article-title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells","volume":"391","author":"Henn","year":"1998","journal-title":"Nature"},{"issue":"6689","key":"10.1016\/j.blre.2024.101220_bb0575","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/28204","article-title":"Reduction of atherosclerosis in mice by inhibition of CD40 signalling","volume":"394","author":"Mach","year":"1998","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0580","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1161\/ATVBAHA.110.207480","article-title":"Platelet-leukocyte interactions in cardiovascular disease and beyond","volume":"30","author":"Totani","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.blre.2024.101220_bb0585","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2174\/0929867325666180508100950","article-title":"Role of Ox-LDL and LOX-1 in Atherogenesis","volume":"26","author":"Kattoor","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.blre.2024.101220_bb0590","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2014.38","article-title":"CD36, a scavenger receptor implicated in atherosclerosis","volume":"46","author":"Park","year":"2014","journal-title":"Exp Mol Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0595","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-0030-1251498","article-title":"Oxidized LDL-activated platelets induce vascular inflammation","volume":"36","author":"Daub","year":"2010","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0600","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/jth.15883","article-title":"The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a danish cohort study","volume":"20","author":"Overvad","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0605","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0610","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.blre.2024.101220_bb0615","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.blre.2024.101220_bb0625","first-page":"785","article-title":"Thrombosis and platelets: an update","volume":"38","author":"Koupenova","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.blre.2024.101220_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.6","article-title":"Venous thrombosis","volume":"1","author":"Wolberg","year":"2015","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0635","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0640","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1538-7836.2009.03680.x","article-title":"High platelet count associated with venous thromboembolism in cancer patients: results from the vienna cancer and thrombosis study (CATS)","volume":"8","author":"Simanek","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0645","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminoncol.2014.04.009","article-title":"Platelets and cancer-associated thrombosis","volume":"41","author":"Connolly","year":"2014","journal-title":"Semin Oncol"},{"issue":"13","key":"10.1016\/j.blre.2024.101220_bb0650","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.blre.2024.101220_bb0655","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb0660","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI60229","article-title":"New insights into the mechanisms of venous thrombosis","volume":"122","author":"Mackman","year":"2012","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0665","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jth.13181","article-title":"Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice","volume":"14","author":"Geddings","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0670","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1515\/cclm-2018-0909","article-title":"Circulating platelet-neutrophil aggregates as risk factor for deep venous thrombosis","volume":"57","author":"Zhou","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0675","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Br\u00fchl","year":"2012","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0680","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0685","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2024.101220_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184606","article-title":"Thrombotic complications associated with immune checkpoint inhibitors","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0695","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0700","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0705","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jacc.2014.03.049","article-title":"Aspirin therapy in primary cardiovascular disease prevention: a position paper of the european society of cardiology working group on thrombosis","volume":"64","author":"Halvorsen","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.blre.2024.101220_bb0710","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet agents for the treatment and prevention of coronary atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0715","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005860","article-title":"EROSION study (effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion): A 1-year follow-up report","volume":"10","author":"Xing","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0720","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/rth2.12080","article-title":"The coagulation system in atherothrombosis: implications for new therapeutic strategies","volume":"2","author":"Olie","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2024.101220_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100619","article-title":"Management of bleeding and procedures in patients on antiplatelet therapy","volume":"39","author":"Swan","year":"2020","journal-title":"Blood Rev"},{"issue":"12","key":"10.1016\/j.blre.2024.101220_bb0730","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/14740338.2019.1680637","article-title":"Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms","volume":"18","author":"Buccheri","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"18","key":"10.1016\/j.blre.2024.101220_bb0735","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2016.02.056","article-title":"Validation of BARC bleeding criteria in patients with acute coronary syndromes: the TRACER trial","volume":"67","author":"Vranckx","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.blre.2024.101220_bb0740","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Group ASC","year":"2018","journal-title":"N Engl J Med"},{"issue":"10152","key":"10.1016\/j.blre.2024.101220_bb0745","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2024.101220_bb0750","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1607181","article-title":"Benefits and risks of clopidogrel vs. aspirin monotherapy after recent ischemic stroke: a systematic review and meta-analysis","volume":"2019","author":"Paciaroni","year":"2019","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0755","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1053\/j.gastro.2018.10.036","article-title":"Risk of postpolypectomy bleeding with uninterrupted clopidogrel therapy in an industry-independent, double-blind, randomized trial","volume":"156","author":"Chan","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0760","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2024.101220_bb0765","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.blre.2024.101220_bb0770","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0775","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jebm.12253","article-title":"Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: a systematic review and meta-analysis","volume":"10","author":"Zhou","year":"2017","journal-title":"J Evid Based Med"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0780","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ajh.10451","article-title":"Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials","volume":"75","author":"Serebruany","year":"2004","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0785","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/jama.2022.12584","article-title":"Effect of intravenous tirofiban vs placebo before endovascular thrombectomy on functional outcomes in large vessel occlusion stroke: the RESCUE BT randomized clinical trial","volume":"328","author":"Qiu","year":"2022","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb0790","article-title":"Targeting the RT loop of Src SH3 in platelets prevents thrombosis without compromising hemostasis","volume":"9","author":"Mao","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"552","key":"10.1016\/j.blre.2024.101220_bb0795","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7287","article-title":"High-loading Galpha13-binding EXE peptide nanoparticles prevent thrombosis and protect mice from cardiac ischemia\/reperfusion injury","volume":"12","author":"Pang","year":"2020","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0800","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10.1016\/j.blre.2024.101220_bb0805","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.tips.2012.07.004","article-title":"Platelet GPVI: a target for antithrombotic therapy?!","volume":"33","author":"Dutting","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0810","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/19420862.2017.1336592","article-title":"Design, development and characterization of ACT017, a humanized fab that blocks platelet\u2019s glycoprotein VI function without causing bleeding risks","volume":"9","author":"Lebozec","year":"2017","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0815","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1161\/CIRCULATIONAHA.112.000799","article-title":"Integrin alpha6beta1 is the main receptor for vascular laminins and plays a role in platelet adhesion, activation, and arterial thrombosis","volume":"128","author":"Schaff","year":"2013","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0820","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","article-title":"Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor","volume":"10","author":"Nylander","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0825","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.13027","article-title":"Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase beta inhibition and aspirin in man","volume":"13","author":"Nylander","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0830","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/ATVBAHA.117.310104","article-title":"PAR4 (protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.blre.2024.101220_bb0835","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood-2014-04-569707","article-title":"CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo","volume":"124","author":"Alshahrani","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2024.101220_bb0840","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood-2012-08-449694","article-title":"Delayed targeting of CD39 to activated platelet GPIIb\/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?","volume":"121","author":"Hohmann","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0845","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC-4: a novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"10.1016\/j.blre.2024.101220_bb0850","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016552","article-title":"First human use of RUC-4: a nonactivating second-generation small-molecule platelet glycoprotein IIb\/IIIa (integrin alphaIIbbeta3) inhibitor designed for subcutaneous point-of-care treatment of ST-segment-elevation myocardial infarction","volume":"9","author":"Kereiakes","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082306","article-title":"A short half-life alphaIIbbeta(3) antagonist ANTP266 reduces thrombus formation","volume":"19","author":"Liu","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"7474","key":"10.1016\/j.blre.2024.101220_bb0860","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nature12613","article-title":"A directional switch of integrin signalling and a new anti-thrombotic strategy","volume":"503","author":"Shen","year":"2013","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.blre.2024.101220_bb0865","doi-asserted-by":"crossref","first-page":"29699","DOI":"10.1074\/jbc.M503508200","article-title":"Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain","volume":"280","author":"Arias-Salgado","year":"2005","journal-title":"J Biol Chem"},{"issue":"23","key":"10.1016\/j.blre.2024.101220_bb0870","doi-asserted-by":"crossref","first-page":"13298","DOI":"10.1073\/pnas.2336149100","article-title":"Src kinase activation by direct interaction with the integrin beta cytoplasmic domain","volume":"100","author":"Arias-Salgado","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb0875","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/pro.2323","article-title":"Structural insights into the recognition of beta3 integrin cytoplasmic tail by the SH3 domain of Src kinase","volume":"22","author":"Katyal","year":"2013","journal-title":"Protein Sci"},{"issue":"25","key":"10.1016\/j.blre.2024.101220_bb0880","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1074\/jbc.M115.648428","article-title":"The tyrosine kinase c-Src specifically binds to the active integrin alphaIIbbeta3 to initiate outside-in signaling in platelets","volume":"290","author":"Wu","year":"2015","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0885","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood-2007-09-110437","article-title":"RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase","volume":"112","author":"Su","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2024.101220_bb0890","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-015-0159-8","article-title":"Evaluation of targeting c-Src by the RGT-containing peptide as a novel antithrombotic strategy","volume":"8","author":"Huang","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.blre.2024.101220_bb0895","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood.2019002314","article-title":"The 14-3-3\u03b6-c-Src-integrin-\u03b23 complex is vital for platelet activation","volume":"136","author":"Shen","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0900","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood-2012-07-440644","article-title":"Structural framework of c-Src activation by integrin beta3","volume":"121","author":"Xiao","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb0905","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ccell.2018.03.002","article-title":"The platelet lifeline to cancer: challenges and opportunities","volume":"33","author":"Haemmerle","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0910","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41467-017-00411-z","article-title":"Platelets reduce anoikis and promote metastasis by activating YAP1 signaling","volume":"8","author":"Haemmerle","year":"2017","journal-title":"Nat Commun"},{"issue":"24","key":"10.1016\/j.blre.2024.101220_bb0915","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1182\/blood-2012-06-438598","article-title":"Platelets increase the proliferation of ovarian cancer cells","volume":"120","author":"Cho","year":"2012","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2024.101220_bb0920","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.1158\/0008-5472.CAN-08-0718","article-title":"Platelet granule secretion continuously prevents intratumor hemorrhage","volume":"68","author":"Ho-Tin-Noe","year":"2008","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0925","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0930","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ccr.2013.05.008","article-title":"Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor","volume":"24","author":"Schumacher","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb0935","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.celrep.2018.03.092","article-title":"Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinates transendothelial migration","volume":"23","author":"Ward","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0940","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0945","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb0950","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-11-1872","article-title":"Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells","volume":"72","author":"Placke","year":"2012","journal-title":"Cancer Res"},{"issue":"30","key":"10.1016\/j.blre.2024.101220_bb0955","doi-asserted-by":"crossref","first-page":"E3053","DOI":"10.1073\/pnas.1411082111","article-title":"Platelets guide the formation of early metastatic niches","volume":"111","author":"Labelle","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0960","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc.2017.6","article-title":"Pre-metastatic niches: organ-specific homes for metastases","volume":"17","author":"Peinado","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb0965","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/ATVBAHA.116.308791","article-title":"Tamoxifen directly inhibits platelet angiogenic potential and platelet-mediated metastasis","volume":"37","author":"Johnson","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0970","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.blre.2024.101220_bb0975","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood-2011-02-334524","article-title":"Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis","volume":"118","author":"Battinelli","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.blre.2024.101220_bb0980","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res"},{"issue":"415","key":"10.1016\/j.blre.2024.101220_bb0985","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci Signal"},{"issue":"11","key":"10.1016\/j.blre.2024.101220_bb0990","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb0995","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-018-0570-z","article-title":"Immunoregulatory functions and the therapeutic implications of GARP-TGF-beta in inflammation and cancer","volume":"11","author":"Metelli","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb1000","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-024-01528-7","article-title":"Targeting inflammation as cancer therapy","volume":"17","author":"Wang","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb1005","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","article-title":"Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance","volume":"35","author":"Cooper","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb1010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10456-009-9141-9","article-title":"Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis","volume":"12","author":"Somanath","year":"2009","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb1015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"10.1016\/j.blre.2024.101220_bb1020","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/0008-5472.CAN-17-1225","article-title":"Bone-induced expression of integrin \u03b23 enables targeted nanotherapy of breast cancer metastases","volume":"77","author":"Ross","year":"2017","journal-title":"Cancer Res"},{"issue":"Pt 14","key":"10.1016\/j.blre.2024.101220_bb1025","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1242\/jcs.114.14.2665","article-title":"Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro","volume":"114","author":"Li","year":"2001","journal-title":"J Cell Sci"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb1030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1389450117666151209115324","article-title":"Therapeutic value of an integrin antagonist in prostate cancer","volume":"17","author":"Philippe","year":"2016","journal-title":"Curr Drug Targets"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb1035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s13045-020-01009-7","article-title":"Abnormally activated OPN\/integrin \u03b1V\u03b23\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer","volume":"13","author":"Fu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.blre.2024.101220_bb1040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","article-title":"Integrins as therapeutic targets","volume":"33","author":"Goodman","year":"2012","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.blre.2024.101220_bb1045","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1080\/21655979.2022.2029236","article-title":"Cilengitide, an alphavbeta3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model","volume":"13","author":"Pan","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.blre.2024.101220_bb1050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CMR.0b013e32835312e4","article-title":"A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma","volume":"22","author":"Kim","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.blre.2024.101220_bb1055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/1471-2407-6-285","article-title":"A randomized multi-center phase II trial of the angiogenesis inhibitor cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer","volume":"6","author":"Friess","year":"2006","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.blre.2024.101220_bb1060","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2007.14.1812","article-title":"Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012","volume":"26","author":"MacDonald","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2024.101220_bb1065","first-page":"549","article-title":"Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb\/IIIa antagonist XV454","volume":"90","author":"Amirkhosravi","year":"2003","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.blre.2024.101220_bb1070","first-page":"131","article-title":"Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins","volume":"29","author":"Engebraaten","year":"2009","journal-title":"Anticancer Res"},{"issue":"10","key":"10.1016\/j.blre.2024.101220_bb1075","first-page":"2824","article-title":"Multiple roles for platelet GPIIb\/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis","volume":"62","author":"Trikha","year":"2002","journal-title":"Cancer Res"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X24000535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T19:10:39Z","timestamp":1724526639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X24000535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":215,"alternative-id":["S0268960X24000535"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2024.101220","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2024.101220","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101220"}}